Our anti-cancer drug screening highlighted several compounds targeting signaling pathways associated with the oncogenic mechanisms of RELAFUS1, such as RTK, HDAC and NF-κB inhibitors including a proteasome inhibitor. The gene discussed is NFKB1; the disease is cancer.